Investment Analysts’ Weekly Ratings Changes for Immunome (IMNM)

Immunome (NASDAQ: IMNM) recently received a number of ratings updates from brokerages and research firms:

• 10/27/2026 – Immunome had its “buy” rating reaffirmed by HC Wainwright.
• 10/27/2026 – Immunome had its “outperform” rating reaffirmed by Wedbush. They now have a $35.00 price target on the stock.
• 10/16/2026 – Immunome is now covered by William Blair. They set an “outperform” rating on the stock.
• 10/15/2026 – Immunome had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/4/2026 – Immunome was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 9/30/2026 – Immunome is now covered by Stifel Nicolaus. They set a “hold” rating and a $24.00 price target on the stock.
• 9/26/2026 – Immunome was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 9/21/2026 – Immunome is now covered by Alliance Global Partners. They set a “buy” rating and a $32.00 price target on the stock.
• 9/10/2026 – Immunome had its “buy” rating reaffirmed by HC Wainwright. They now have a $40.00 price target on the stock.

Immunome Trading Down 8.2%

NASDAQ:IMNM traded down $1.61 on Thursday, reaching $17.91. The stock had a trading volume of 2,206,712 shares, compared to its average volume of 1,381,070. The company has a 50-day moving average of $21.91 and a 200 day moving average of $22.45. The stock has a market cap of $2.03 billion, a P/E ratio of -7.08 and a beta of 2.68. Immunome, Inc. has a 12-month low of $14.64 and a 12-month high of $30.06.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). On average, equities analysts predict that Immunome, Inc. will post -2.48 EPS for the current year.

Insider Buying and Selling at Immunome

In other news, insider Jack Higgins sold 13,200 shares of the business’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $25.32, for a total value of $334,224.00. Following the completion of the sale, the insider owned 65,050 shares of the company’s stock, valued at approximately $1,647,066. The trade was a 16.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 11,048 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $27.25, for a total transaction of $301,058.00. Following the completion of the sale, the director owned 92,211 shares in the company, valued at approximately $2,512,749.75. This trade represents a 10.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 111,912 shares of company stock worth $2,930,497 over the last ninety days. 7.21% of the stock is currently owned by corporate insiders.

Immunome, Inc (NASDAQ: IMNM) is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based medicines. Its technology platform analyzes human immune responses to identify antibodies that may be developed into therapies for serious diseases.

The company’s research activities have included therapeutic programs in oncology and immunology, with an emphasis on antibodies designed to affect disease-driving biological pathways. Immunome has also conducted antibody discovery work related to infectious diseases, including SARS-CoV-2, as it has expanded its focus toward broader therapeutic applications.

Immunome is headquartered in Exton, Pennsylvania, and serves the global biopharmaceutical market through internal research and development activities and potential collaborations.